Navigation Links
Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
Date:1/24/2008

PALATINE, Ill., Jan. 24 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (OTC Bulletin Board: ACPH.OB) is pleased to announce the appointment of George K. Ross to its Board of Directors and Chairman of its Audit Committee. The appointment of Mr. Ross increases the size of the Company's Board to seven.

Since April 2002, Mr. Ross has been a consultant to early stage businesses and a financial investor. Since July 2005 he has also served as Executive Director, Greater New York for World Vision. His business career has included senior financial officer and board member positions with both public and private companies in diverse industries. Mr. Ross was Executive Vice President and Chief Financial Officer and a board member of Tier Technologies Inc. from February 1997 to January 2000, which became a public company during this period. Mr. Ross was a partner and investor with Capital Partners from 1992 to 1997, serving on multiple boards of directors. He was a senior financial officer and director of various Axel Johnson Inc. businesses from 1979 to 1992. He also served as Executive Vice President and Chief Financial Officer and director of Aminoil USA, an R.J. Reynolds ("RJR") subsidiary, from 1976 to 1979; and in various financial positions with RJR from 1969 to 1976. He also has worked in public accounting with Ernst & Ernst. Mr. Ross is a Certified Public Accountant and earned a Bachelor of Arts degree from Ohio Wesleyan University and a Masters of Business Administration from Ohio State University.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, the ability of the Company, King Pharmaceuticals Research and Development, Inc. and other pharmaceutical companies, if any, with whom the Company may license its Aversion(R) Technology, to obtain necessary regulatory approvals and commercialize products utilizing the Aversion(R) Technology, the ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, the ability to manufacture products utilizing the Aversion(R) Technology, and the ability to fulfill the FDA's requirements for approving the Company's product candidates for commercial distribution in the United States, including, without limitation, the adequacy of the results of the clinical studies completed to date and the results of other clinical studies, to support FDA approval of the Company's product candidates, the adequacy of the development program for the Company's product candidates, changes in regulatory requirements, adverse safety findings relating to the Company's product candidates, the risk that the FDA may not agree with the Company's analysis of its clinical studies and may evaluate the results of these studies by different methods or conclude that the results of the studies are not statistically significant, clinically meaningful or that there were human errors in the conduct of the studies or otherwise, the risk that further studies of the Company's product candidates are not positive, and the uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process. You are encouraged to review other important risk factors relating to the Company on our web site at http://www.acurapharm.com under the link, "Company Risk Factors" and detailed in Company filings with the Securities and Exchange Commission. Acura Pharmaceuticals, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Acura Pharmaceuticals, Inc. press releases may be reviewed at http://www.acurapharm.com.


'/>"/>
SOURCE Acura Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
2. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
3. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
4. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
5. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
6. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
9. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
10. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
11. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Texas (PRWEB) , ... May 25, 2016 , ... The ... Myers Veterans Biomedical Technology Program to help provide veterans a pathway to employment and ... Executive, presented a $20,000 check to Nick Hallack, President and CEO of Medisend, parent ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... International University (FIU) Herbert Wertheim College of Medicine announced the AUA-FIU Global MD ... Degree and Global Health Certificate from AUA and a Certificate of Completion from ...
(Date:5/25/2016)... O'Fallon, MO (PRWEB) , ... May 25, 2016 , ... ... located in Woodlawn Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients ... and cosmetic treatments . Dr. Schwarz’s success is reflected in the superior ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading destination ... innovative workshops and training opportunities in the growing field of yoga therapy ... who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic health ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of ... McKenna ran one of Allstate’s most successful agencies for 48 years, but it was ... The award named for him is not given every year, but only when an ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016 ARANZ Medical ... the healthcare sector, has been named the Coretex Hi-Tech Emerging ... 2016. Dr Bruce Davey , CEO of ... team.  It,s really good to be recognised for the work ... products are used in 35 countries around the world from ...
(Date:5/24/2016)... , May 24, 2016 ... doble terapia del mundo, introduce catéteres para la ... OrbusNeich, una compañía global especializada en el ... ha expandido su cartera incluyendo productos para tratar ... y Scoreflex™ PTA son los dispositivos de primera ...
Breaking Medicine Technology: